Neurocrine Biosciences, Inc. presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia (TD) among the majority of patients treated with once-daily INGREZZA capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.
The post-hoc analysis, using data from 103 participants who reached the final Week 48 visit, assessed a proposed threshold for remission of TD symptoms using the Abnormal Involuntary Movement Scale (AIMS). A majority of participants, specifically 59.2% on 80 mg and 58.3% on 40 mg, reached the threshold for remission of TD while on treatment, regardless of underlying psychiatric diagnosis or dose.
These findings further establish INGREZZA as a highly effective long-term treatment option for individuals living with tardive dyskinesia, including those with schizophrenia, schizoaffective disorder, or mood disorder. The significant improvements observed in AIMS score and high remission rates highlight INGREZZA's efficacy, even at the lowest dose.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.